Home » Stocks » ACST

Acasti Pharma Inc. (ACST)

Stock Price: $0.625 USD -0.005 (-0.84%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $0.720 +0.095 (15.18%) Mar 8, 7:21 PM
Market Cap 113.25M
Revenue (ttm) 81,000
Net Income (ttm) 3.07M
Shares Out 110.47M
EPS (ttm) 0.03
PE Ratio 23.15
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $0.625
Previous Close $0.630
Change ($) -0.005
Change (%) -0.84%
Day's Open 0.642
Day's Range 0.601 - 0.678
Day's Volume 24,300,879
52-Week Range 0.171 - 1.220

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 hours ago

LAVAL, Quebec, March 08, 2021 (GLOBE NEWSWIRE) -- As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) i...

Proactive Investors - 1 week ago

TRILOGY 2 study on CaPre did not meet its primary endpoint CaPre was a krill-oil derived prescription drug designed to treat hypertriglyceridemia What Acasti Pharma does: Acasti Pharma Inc (NA...

Benzinga - 3 weeks ago

Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Th...

Other stocks mentioned: CORT
Proactive Investors - 3 weeks ago

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) (FRA:A1PA), which is currently going through a review process aimed at enhancing shareholder value, posted Tuesday its fiscal third-quarter results t...

GlobeNewsWire - 3 weeks ago

LAVAL, Quebec, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) today announced its operating and financial results for the third qu...

GlobeNewsWire - 1 month ago

LAVAL, Québec, Jan. 27, 2021 (GLOBE NEWSWIRE) -- As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) is...

InvestorPlace - 1 month ago

Acasti Pharma (ACST) stock is on the rise Monday with heavy trading of its shares despite a lack of news concerning the company. The post ACST Stock Alert: 13 Things for Acasti Pharma Investor...

Zacks Investment Research - 2 months ago

Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 2 months ago

LAVAL, Québec, Dec. 23, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company's manage...

InvestorPlace - 2 months ago

ACST stock is up more than 100% on Wednesday without any news about Acasti Pharma. Here's what you should know.

GlobeNewsWire - 3 months ago

LAVAL, Quebec, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) today provided a business update and announced its operating and fin...

GlobeNewsWire - 5 months ago

LAVAL, Québec, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST – TSX-V: ACST), announces the voting results for the matters listed in its man...

GlobeNewsWire - 5 months ago

Additional analyses of TRILOGY data underway Additional analyses of TRILOGY data underway

GlobeNewsWire - 5 months ago

LAVAL, Québec, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has appointed seasoned financial executive Bri...

GlobeNewsWire - 5 months ago

LAVAL, Québec, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has filed and mailed the information circular ...

GlobeNewsWire - 6 months ago

CaPre achieved a 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint CaPre achieved a 30.4% median ...

Zacks Investment Research - 6 months ago

Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 7 months ago

LAVAL, Québec, July 31, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, developm...

Benzinga - 8 months ago

Acasti Pharma (NASDAQ: ACST) shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share.

Seeking Alpha - 8 months ago

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q4 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Identifies “Triglyceride Normalization” phenomenon prior to patient randomization and treatment  as likely contributor to unusually high placebo effect in TRILOGY 1

GlobeNewsWire - 8 months ago

Plans to report summary of Trilogy 1 data on June 29, 2020 conference call Plans to report summary of Trilogy 1 data on June 29, 2020 conference call

GlobeNewsWire - 10 months ago

FDA response expected on or before June 30, 2020

GlobeNewsWire - 10 months ago

Expands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids Expands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids

GlobeNewsWire - 11 months ago

LAVAL, Québec, April 01, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, developm...

GlobeNewsWire - 1 year ago

LAVAL, Québec, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, developme...

InvestorPlace - 1 year ago

It doesn't look good for Acasti Pharma stock. If they plan on doubling-down on CaPre, they need more capital.

InvestorPlace - 1 year ago

Acasti Pharma stock plunged after the company reported negative trial results. The company's road ahead is filled with risks.

InvestorPlace - 1 year ago

Acasti Pharma stock collapsed following an unsuccessful Phase 3 clinical trial. But even this major setback isn't the only headwind impacting shares.

Seeking Alpha - 1 year ago

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2020 Results - Earnings Call Transcript

InvestorPlace - 1 year ago

Acasti Pharma stock jumped higher last year on the potential of Acasti’s krill-oil extract CaPre. But a closer examination of its Phase 3 results suggests not all is well with the company.

InvestorPlace - 1 year ago

Acasti's Phase 3 trial of CaPre, aimed at patients with high levels of triglycerides, isn't working out, explaining why the stock is down 69.11% to start 2020. One of the primary causes of con...

GlobeNewsWire - 1 year ago

Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1

InvestorPlace - 1 year ago

Acasti Pharma lost $118 million in market capitalization on January 13. That makes Acasti Pharma stock a liability, not a bargain.

InvestorPlace - 1 year ago

Acasti Pharma stock plunged after disappointing TRILOGY 1 trial results. TRILOGY 2 results in February mark the company's last chance.

InvestorPlace - 1 year ago

Following unsuccessful Phase 3 clinical trial results for its core CaPre treatment, Acasti and ACST stock look doomed. The post The Future Doesn’t Look Too Bright For Acasti Pharma Stock appea...

InvestorPlace - 1 year ago

Acasti hopes a second study of its CaPre drug, due for release next month, shows better results, but most investors have left ACST stock. The post Acasti’s Losing Drug and ACST Stock Are Not f...

InvestorPlace - 1 year ago

Acasti got some bad news recently from the FDA regarding its main drug candidate. And this news could make it tough for ACST stock to recover.

InvestorPlace - 1 year ago

ACST stock was already a tough gamble due to the competition for omega-3-based drugs. However, without FDA approval, the underlying pharmaceutical is merely a gamble.

Market Watch - 1 year ago

Shares of Amarin Corp. PLC AMRN, +4.80% rose 4.8% in active afternoon trading Monday, after makers of drugs that rival Amarin's Vascepa, which is used to lower the risk of cardiovascular event...

Other stocks mentioned: AMRN, AZN
Benzinga - 1 year ago

Shares of Acasti Pharma Inc (NASDAQ: ACST), which closed at $2.18 Friday, have entered penny stock territory after a negative data readout.

InvestorPlace - 1 year ago

When Acasti posts Phase 3 trial results, ACST stock could re-visit recent highs. Here's why you should pay attention to the stock now.

GlobeNewsWire - 1 year ago

Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride lev...

Benzinga - 1 year ago

Micro-cap biopharma Acasti Pharma Inc (NASDAQ: ACST) issued an update regarding a delay in a clinical readout.

GlobeNewsWire - 1 year ago

Expects to report Trilogy 1 topline results in January 2020 with topline results for Trilogy 2 still expected by the end of January 2020

InvestorPlace - 1 year ago

Acasti Pharma (ACST) is having trouble on Monday as ACST stock has fallen a great deal, but what's behind the falling prices? The post Acasti Pharma News: Why ACST Stock Is Plummeting 24% Toda...

GlobeNewsWire - 1 year ago

On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020 On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

Seeking Alpha - 1 year ago

Acasti's Value Hidden In Plain Sight

Seeking Alpha - 1 year ago

Acasti Pharma - Winning The Heart Race

GlobeNewsWire - 1 year ago

LAVAL, Québec, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, developmen...

About ACST

Acasti Pharma, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Industry
Biotechnology
CEO
Janelle D'Alvise
Employees
32
Stock Exchange
NASDAQ
Ticker Symbol
ACST
Full Company Profile

Financial Performance

Financial numbers in millions CAD.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for Acasti Pharma stock is "Hold" and the 12-month stock price forecast is 2.52.

Price Target
$2.52
Analyst Consensus: Hold